RENB.Renovaro INC
10-Q/A: Renovaro Inc. Restates Q1 2025 Financials Due to Warrant Exercise Error, Reports Significant Goodwill Impairment
Sentiment:
Quarterly Report Amendment (Form 10-Q/A)
Renovaro Inc. is restating its Q1 2025 financial statements due to a material misstatement related to the exercising of certain warrants, and reports a significant goodwill impairment charge.
Capital raiseThe company's ability to continue as a going concern is dependent on securing additional funding through equity or debt financing.The company intends to secure additional required funding through equity or debt financing.Such additional funding may not be available or may not be available on reasonable terms, and, in the case of equity financing transactions, could result in significant additional dilution to our stockholders.
Worse than expectedThe company is restating its financial statements due to a material misstatement.The company incurred a significantly larger net loss compared to the same period last year.The company recorded a substantial goodwill impairment charge.The company has a significant working capital deficit and limited cash reserves.
Summary
- Renovaro Inc. is filing an amendment to its Q1 2025 report to restate its financial statements as of and for the period ended September 30, 2024.
- The restatement is due to a material misstatement related to the exercising of certain warrants, which impacted the change in fair value of the contingent consideration liability during the year ended June 30, 2024.
- The company's management re-evaluated the effectiveness of the company's internal control over financial reporting (ICFR) as of September 30, 2024, and believes the error relates to a previously identified and reported material weakness.
- For the three months ended September 30, 2024, the company reported a net loss of $44,212,036, compared to a net loss of $9,175,028 for the same period in 2023.
- The company recognized a goodwill impairment charge of $47,614,729 during the quarter ended September 30, 2024.
- As of September 30, 2024, the company had cash and cash equivalents of $220,571 and an accumulated deficit of $376,667,117.
- The company has a working capital deficit of $21,087,220 as of September 30, 2024.
- The company's ability to continue as a going concern is dependent on securing additional funding through equity or debt financing.
- The company is involved in several legal proceedings, including securities class action litigation and derivative litigation.
- The company is focusing on the development and validation of its AI-driven cancer diagnostics platform.
Sentiment
Score: 3
Explanation: The document presents a negative outlook due to the restatement of financials, significant losses, goodwill impairment, and going concern uncertainties. The company's dependence on additional funding and involvement in legal proceedings further contribute to the low sentiment score.
Positives
- Management has reduced overhead and administrative costs by streamlining the organization.
- The company is focusing on the development and validation of its AI-driven cancer diagnostics platform.
- The company intends to secure additional required funding through equity or debt financing.
Negatives
- The company is restating its Q1 2025 financial statements due to a material misstatement.
- The company's previously issued unaudited interim condensed consolidated financial statements for the quarter ended September 30, 2024, should no longer be relied upon.
- The company incurred a net loss of $44,212,036 for the quarter ended September 30, 2024.
- A goodwill impairment adjustment of $47,614,729 was recorded for the period ended September 30, 2024.
- As of September 30, 2024, the company had cash and cash equivalents of $220,571 and an accumulated deficit of $376,667,117.
- The company has a working capital deficit of $21,087,220 as of September 30, 2024.
- The company has identified a material weakness in controls over financial reporting.
- The company is involved in several legal proceedings, including securities class action litigation and derivative litigation.
Risks
- The company's ability to continue as a going concern is dependent on securing additional funding through equity or debt financing, which may not be available.
- Failure to obtain required additional equity or debt funding could require the company to materially reduce or suspend operations.
- Adverse outcomes in legal or regulatory proceedings could adversely affect the company's liquidity and financial position.
- The company may never be profitable.
- The company's disclosure controls and procedures were not effective in ensuring that the information we were required to disclose in reports that we file or submit under the Securities and Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms.
Future Outlook
The company's future is dependent on securing additional funding through equity or debt financing to support operations, commercialization, and clinical development.
Management Comments
- Management has reduced overhead and administrative costs by streamlining the organization to focus around the development and validation of its AI-driven cancer diagnostics platform.
- The Company has tailored its workforce to focus on these activities.
- In addition, the Company intends to secure additional required funding through equity or debt financing.
Industry Context
The company operates in the biotechnology and AI-driven healthcare technology sectors, focusing on cancer diagnostics and therapeutics, which are areas of significant investment and innovation.
Comparison to Industry Standards
- The company's focus on AI-driven cancer diagnostics aligns with the broader industry trend of leveraging artificial intelligence for early detection and personalized treatment.
- Companies like GRAIL (acquired by Illumina) and Exact Sciences are also focused on early cancer detection using liquid biopsies and advanced analytics.
- Renovaro Cube's approach of using Explainable AI to analyze genetics for cancer diagnosis is similar to other companies using AI to identify biomarkers and patterns in complex data sets.
- The company's allogeneic cell therapy platform for cancer treatment is comparable to other companies developing cell and gene therapies, such as Kite Pharma (acquired by Gilead) and Novartis.
- However, Renovaro's financial situation, with substantial losses and dependence on additional funding, is a significant challenge compared to larger, more established companies in the industry.
Legal Proceedings
- The company is involved in several legal proceedings, including securities class action litigation, federal derivative litigation, and state derivative litigation.
- The company filed a Complaint in the Superior Court of the State of California for the County of Los Angeles against Serhat Gmrkc, William Anderson Wittekind (Wittekind), G Tech Bio, SG & AW Holdings, LLC, and SRI (collectively, the Defendants).
- On March 1, 2021, the Companys former Chief Financial Officer, Robert Wolfe and his company, Crossfield, Inc., filed a Complaint in the U.S. District Court for the District of Vermont against the Company, Renovaro Biosciences Denmark ApS, and certain directors and officers.
- On June 7, 2023, Weird Science LLC (Weird Science), Wittekind, the William Anderson Wittekind 2020 Annuity Trust, the William Anderson Wittekind 2021 Annuity Trust, the Dybul 2020 Angel Annuity Trust, and the Ty Mabry 2021 Annuity Trust (collectively, the Trusts) (collectively, Plaintiffs) filed a Verified Complaint against the Company in the Court of Chancery of Delaware.
- On June 21, 2024, the Company filed suit against Weird Science, Wittekind, and certain trusts in connection with the February 16, 2018 merger involving the Company and two companies closely associated with Gumrukcu.
Related Party Transactions
- As of September 30, 2024, the Company has accrued $ 283,652 of compensation related expenses for the Companys former Chief Executive Officer, Mark Dybul, related to budget constraints.
- On August 23, 2024, Avram Miller, a former member of the Board of Directors, forfeited 833,333 shares of Common Stock from the original 1,000,000 shares of Common Stock for advisory services originally granted to him on October 11, 2023.
Stakeholder Impact
- Shareholders face potential dilution from future equity financing.
- Employees may be affected by potential reductions or suspensions of operations if funding is not secured.
- The company's ability to develop and commercialize its products and technologies could impact patients and healthcare providers.
- Creditors face increased risk due to the company's financial difficulties and dependence on additional funding.
Next Steps
- The company intends to secure additional required funding through equity or debt financing.
- The company will continue to defend against ongoing legal proceedings.
- The company will continue to focus on the development and validation of its AI-driven cancer diagnostics platform.
- The plaintiffs deadline to file a motion for preliminary approval of the settlement is December 9, 2024.
- The parties deadline to file a joint status report in the Koenig matter is January 10, 2025.
- Trial is currently scheduled to begin on March 3, 2025.
- The Court reset the trial date for May 6, 2025.
Key Dates
| Date | Description |
|---|---|
| 2011-01-18 | Company incorporated as Putnam Hills Corp. |
| 2018-02-16 | Date of merger involving the Company and two companies closely associated with Gumrukcu. |
| 2018 | Grace Systems began applying its algorithms to biological data in 2018 to uncover cancer-associated patterns. |
| 2020-01-31 | Company entered into a Statement of Work and License Agreement (the HBV License Agreement) with G Tech Bio, LLC, a California limited liability company (G Tech), and G Health Research Foundation, a not-for-profit entity organized under the laws of California doing business as Seraph Research Institute (SRI) (collectively the Licensors). |
| 2020-03-30 | Company issued a Promissory Note in the principal amount of $5,000,000 to Paseco ApS. |
| 2021-04-18 | Company entered into a Statement of Work and License Agreement (the License Development Agreement), by and among the Company, G Tech and SRI (collectively, the Licensors). |
| 2021-08-25 | Company entered into an ALC Patent License and Research Funding Agreement in the HIV Field (the ALC License Agreement) with Serhat Gmrkc and SRI (collectively, the Licensors). |
| 2022-07-26 | Securities class action complaints (the Chow Action) were filed by purported stockholders of the Company in the United States District Court for the Central District of California against the Company and certain of the Companys current and former officers and directors. |
| 2022-07-28 | Securities class action complaints (the Manici Action) were filed by purported stockholders of the Company in the United States District Court for the Central District of California against the Company and certain of the Companys current and former officers and directors. |
| 2022-09-22 | Samuel E. Koenig filed a shareholder derivative action in the United States District Court for the Central District of California. |
| 2022-10-20 | Susan Midler filed a shareholder derivative action in the Superior Court of California, Los Angeles County. |
| 2022-10-21 | Company filed a Complaint in the Superior Court of the State of California for the County of Los Angeles against Serhat Gmrkc, William Anderson Wittekind (Wittekind), G Tech Bio, SG & AW Holdings, LLC, and SRI (collectively, the Defendants). |
| 2023-01-19 | John Solak filed a substantially similar shareholder derivative action in the United States District Court for the District of Delaware. |
| 2023-03-01 | The Companys former Chief Financial Officer, Robert Wolfe and his company, Crossfield, Inc., filed a Complaint in the U.S. District Court for the District of Vermont against the Company, Renovaro Biosciences Denmark ApS, and certain directors and officers. |
| 2023-06-07 | Weird Science LLC (Weird Science), Wittekind, the William Anderson Wittekind 2020 Annuity Trust, the William Anderson Wittekind 2021 Annuity Trust, the Dybul 2020 Angel Annuity Trust, and the Ty Mabry 2021 Annuity Trust (collectively, the Trusts) (collectively, Plaintiffs) filed a Verified Complaint against the Company in the Court of Chancery of Delaware. |
| 2023-06-20 | Company entered into a purchase agreement (the 2023 Purchase Agreement) with Lincoln Park Capital Fund, LLC (Lincoln Park). |
| 2023-09-16 | Company entered into an agreement with RS Bio ApS, a Danish entity controlled by a shareholder (RS Bio), to issue a Promissory Note for the principal amount of $100,000 (the September 2024 Note). |
| 2023-09-28 | Company, entered into a Stock Purchase Agreement (the Purchase Agreement ) with GEDi Cube Intl Ltd., a private company formed under the laws of England and Wales ( GEDi Cube ) to acquire 100% of the equity interests of GEDi Cube from its equity holders (the Sellers ). |
| 2023-11-03 | Company entered into an agreement with RS Bio to issue a 5% Original Issue Discount Promissory Note for the principal amount of $1,000,000. |
| 2023-12-20 | Company entered into Subscription Agreements to purchase Convertible Promissory Notes for an aggregate principal amount of $120,000 (the December 2023 Notes). |
| 2024-01-12 | Company entered into Subscription Agreements with an investor to issue a Convertible Promissory Note for an aggregate principal amount of $125,000 (the January 2024 Note). |
| 2024-02-05 | Company entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $105,263 (the February 2024 Note). |
| 2024-02-13 | Company changed its corporate name from Renovaro Biosciences Inc. to Renovaro Inc. and consummated the acquisition of GEDi Cube. |
| 2024-06-14 | Renovaro Inc. closed a private placement of 5,315,215 of the Companys units, each such Unit consisting of (i) one share of the Companys Common Stock and (ii) one common stock purchase warrant to purchase one-tenth of a share of Common Stock, with certain investors (the June 2024 Private Placement). |
| 2024-07-03 | Related to the June 2024 Private Placement, ranging from July 3, 2024, to September 16, 2024, the Company sold 1,423,456 Units at a price per Unit equal to $ 1.4726 to a certain investor who paid in cash an aggregate amount of $ 2,096 ,181 in consideration of the Units. |
| 2024-08-01 | The principal amount of the Promissory Note, as amended, was payable on November 1, 2024 (the Maturity Date). |
| 2024-08-23 | Avram Miller, a former member of the Companys board of directors (the Board of Directors), forfeited 833,333 shares of Common Stock from the original 1,000,000 shares of Common Stock for advisory services originally granted to him on October 11, 2023. |
| 2024-09-06 | Renovaro Cube entered into an agreement with Paseco ApS, a Danish entity controlled by a shareholder (Paseco ApS), to issue a Promissory Note for the principal amount of 50,000 . |
| 2024-09-17 | A mediation was held on September 17, 2024, after which the parties signed a stipulation of settlement, dated November 8, 2024. |
| 2024-10-01 | On October 1, 2024, the defendants moved to dismiss the complaint. |
| 2024-10-14 | Company issued 250,000 shares of Common Stock as part of a sign on bonus valued at $ 137,500 to the Chief Executive Officer effective October 14, 2024, David Weinstein. |
| 2024-10-17 | Company entered into an investor relations consulting agreement with MZHCI, LLC. Pursuant to the agreement, the Company issued 160,000 shares of Common Stock to MZHCI, LLC valued at $ 118,400 . |
| 2024-10-21 | Company filed suit against Weird Science, Wittekind, and certain trusts in connection with the February 16, 2018 merger involving the Company and two companies closely associated with Gumrukcu. |
| 2024-10-29 | The court granted the director defendants motion to dismiss and dismissed the Derivative Complaint without prejudice, but also without leave to amend. |
| 2024-11-07 | The Court reset the trial date for May 6, 2025. |
| 2024-11-08 | The parties signed a stipulation of settlement, dated November 8, 2024. |
| 2024-11-11 | As of November 11, 2024, the number of shares of the registrants Common Stock outstanding was 158,717,342 . |
| 2024-11-15 | A hearing is scheduled for November 15, 2024. |
| 2024-12-09 | The plaintiffs deadline to file a motion for preliminary approval of the settlement is December 9, 2024. |
| 2025-01-10 | The parties deadline to file a joint status report in the Koenig matter is January 10, 2025. |
| 2025-03-03 | Trial is currently scheduled to begin on March 3, 2025. |
| 2025-05-06 | The Court reset the trial date for May 6, 2025. |
| 2025-08-23 | At September 30, 2024, the Company had $ 1,122,537 of unrecognized compensation cost related to the options which vest at August 23, 2025. |
Keywords
restatement, financial statements, warrants, goodwill impairment, net loss, going concern, legal proceedings, AI-driven cancer diagnostics, Renovaro, funding, liquidity, material weakness, internal control
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.